A Phase 1, Three-Period, Randomized, Double-Blind, Placebo-Controlled, Multiple- Center, Multiple-Dose Study to Assess the Safety and Pharmacokinetics of ZYN002 Administered as a Transdermal Gel to Healthy Subjects and Patients with Epilepsy
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2016
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Zynerba Pharmaceuticals
- 05 Dec 2016 According to a Zynerba Pharmaceuticals media release, results from this study reported at the 70th Annual Meeting of the American Epilepsy Society (AES).
- 05 Dec 2016 Results published in the Zynerba Pharmaceuticals Media Release.
- 28 Nov 2016 According to a Zynerba Pharmaceuticals media release, data from this trial will be presented at the 70th Annual Meeting of the American Epilepsy Society